C
Cytoo
Preclinical stage drug discovery company specialized in muscular and neuromuscular disorders
About Cytoo
CYTOO operates as a Contract Research Organization specializing in the development of physiologically relevant cell-based assays. The company leverages its proprietary micropattern technologies to create cellular models that closely mimic in vivo conditions, thereby enhancing the accuracy and relevance of drug discovery processes. CYTOO's platform is fully compatible with High Content Screening (HCS) and High Content Analysis (HCA), making it a valuable tool for pharmaceutical companies and research institutions. The company collaborates with major industry players, such as Pfizer and AskBio, to advance research in areas like Duchenne Muscular Dystrophy and gene therapy for rare muscle disorders. CYTOO's business model revolves around providing customized research solutions and forming strategic partnerships to drive innovation in drug development. The company generates revenue through contract research services and collaborative agreements. Key offerings include advanced models for cardiomyocytes, myotubes, and renal proximal tubules, each designed to provide more accurate insights into cellular behavior and drug efficacy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Grenoble, France
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 62.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Techbio Drug Discovery, Horizon Europe, observatoire industrial tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Cytoo is 180 monthly website visits, down 87.1% over the last three months. Cytoo's team declined 9.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Auriga Partners (Paris)
CEA Investissement
Auriga Partners
Series B and later1 investor entered at this stage
Entrepreneurs Fund
Other known investors6 additional known investors
HEC Paris
French Alternative Energies and Atomic Energy Commission - CEA
French National Centre for Scientific Research - CNRS
HEC Challenge+
Institut Curie
North Shore InnoVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytoo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytoo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.